Researcher

Xinyi Su graduated with MB BChir PhD from University of Cambridge, UK. Currently, she balances her time as Acting Executive Director of the Institute of Molecular and Cell Biology (IMCB) whilst practising as Senior Consultant Vitreo-Retinal Surgeon (NUH). Su is also the Research Director at the Department of Ophthalmology (NUS), and Clinician-Scientist at SERI.
Her research focuses on harnessing biomaterial, regenerative stem-cell and nucleic acid technologies for the treatment of retinal degenerative disease. Her work has been published in Nature Biomedical Engineering, Nature Communications, Lancet Global Health, PNAS and Advanced Materials. With a career total of > S$25 million in competitive research grants, Su is the recipient of multiple awards including the APAO Young Ophthalmologist Award (2019), APVRS LDP Gold Award (2020), Ten Outstanding Young Persons of Singapore Award (2021), Susan Lim Outstanding Stem Cell Young Investigator Award (2022) and NMRC Clinician Scientist Award (2022). In 2022, she was accepted into the prestigious international membership of The Macular Society.

Passionate about clinical translation, Su holds several patents and co-founded Vitreogel Innovations, focused on developing next-gen vitreous substitutes. Beyond research, Su is committed to talent development. She has mentored numerous clinician scientists as Deputy Director of the Clinician-Scientist Academy (NUHS).